Author

T. Nerreter

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Assay:fluorescence / live-cell microscopy· 1 Approach:microscopy & imaging analysis· 1 Assay:proteomics· 1

Frequent Co-Authors

M. Hudecek· 2 shared A. Ghosh· 1 shared A. Holtermann· 1 shared C. Schultheiss· 1 shared C. Verbruggen· 1 shared D. Anz· 1 shared F. Maerkl· 1 shared H. Einsele· 1 shared

Activity by Year

2023-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

M. Hudecek

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Mutation-specific CAR T cells as precision therapy for IGLV3-21R110 expressing high-risk chronic lymphocytic leukemia

F. Maerkl, C. Schultheiss, M. Ali, S.-S. Chen, L. Egli, J. Mietz, O. Chijoke, L. Paschold, S. Spajic, A. Holtermann, J. Doerr, S. Stock, I. Piseddu, D. Anz, M. Duehren-von Minden, , M. Binder

This study develops CAR T cells targeting a specific mutation in CLL to selectively kill cancer cells while sparing healthy B cells.

bioRxiv · Sep 29, 2023 · PreprintCancer Biology

CARs are organized in nanodomains in the plasma membrane of T cells that accumulate at tumor contact sites

C. Verbruggen, L. Gehrke, N. Banholzer, A. Ghosh, S. Reinhard, J. Weber, S. Doose, H. Einsele, M. Hudecek, T. Nerreter, M. Sauer

This study uses super-resolution microscopy to show CARs form nanodomains on T-cell membranes, accumulating at tumor sites, with transposon-engineered CARs showing higher density and faster anti-tumor activity.

bioRxiv · Jul 19, 2023 · PreprintImmunology